Pyridin-2-one derivatives of formula (I) useful as EP3 receptor antagonists

A compound of formula (I)

• wherein
• is selected from the group consisting of naphth-2-yl, indol-5-yl, indazol-5-yl, indazol-6-yl, benzimidazol-5-yl, benzimidazol-6-yl, benzothiazol-5-yl, benzothiazol-6-yl, benzoisothiazol-6-yl, chroman-7-yl, chromen-7-yl, benzo[d][1,3]dioxol-5-yl, 3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl, 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl and 2,3-dihydro-benzo[b][1,4]dioxin-6-yl;
• wherein the naphth-2-yl, indol-5-yl, indazol-5-yl, indazol-6-yl, benzimidazol-5-yl, benzimidazol-6-yl, benzothiazol-5-yl, benzothiazol-6-yl, benzoisothiazol-6-yl, chroman-7-yl, chromen-7-yl, benzo[d][1,3]dioxol-5-yl, 3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl, 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl or 2,3-dihydro-benzo[b][1,4]dioxin-6-yl;
• is optionally substituted on the phenyl portion of the
• bicycle with one to two substituents independently selected from the group consisting of halogen, oxo, cyano, C1-3alkyl, fluorinated C1-2alkyl, C1-3alkoxy, fluorinated C1-2alkoxy and C3-6cycloalkyl;
• and wherein the naphth-2-yl, indol-5-yl, indazol-5-yl, indazol-6-yl, benzimidazol-5-yl, benzimidazol-6-yl, benzothiazol-5-yl, benzothiazol-6-yl, benzoisothiazol-6-yl, chroman-7-yl, chromen-7-yl, benzo[d][1,3]dioxol-5-yl, 3,4-dihydro-2H-benzo[b][1,4]oxazin-6-yl, 3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yl or 2,3-dihydro-benzo[b][1,4]dioxin-6-yl;
• is further optionally substituted on the
• portion of the
• bicycle with one to two substituents independently selected from the group consisting of halogen, oxo, cyano, C1-3alkyl, fluorinated C1-2alkyl, C1-3alkoxy, fluorinated C1-2alkoxy and C3-6cycloalkyl;
• R1 is selected from the group consisting of hydrogen, halogen and C1-4alkyl;
• R2 is selected from the group consisting of hydrogen, halogen and C1-4 alkyl;
• is selected from the group consisting of —CRARB—, —CRARB—CH2—, —CH2—CHRC—, —CRARB—CRC═, —C(RA)═, —CRARB—N(RD)—, —CRARB—CH2—N(RD)—, —CRARB—C(O)—N(RD)—, —CRARB—CH2—C(O)—N(RD)—, —CRARB—C(O)—N(RD)—SO2—, —CRARB—CH2—C(O)—N(RD)—SO2—, —CRARB—N(RD)—SO2—, —CRARB—CH2—N(RD)—SO2, and —CRARB—CH2—SO2—;
• wherein the X group is incorporated in the orientation as listed;
• wherein RA and RB are each independently selected from the group consisting of hydrogen, fluoro, C1-6alkyl, fluorinated C1-2alkyl, C3-6cycloalkyl, phenyl, benzyl, phenyl-ethyl- and —C(O)—OC2alkyl;
• provided that when one of RA or RB is C3-6cycloalkyl, phenyl, benzyl, phenyl-ethyl- or —C(O)O-C2alkyl, then the other of RA or RB is hydrogen;
• alternatively, when X is selected from the group consisting of —CRARB—, —CRARB—CH2— and —CRARB—CRC═, RA and RB may be taken together with the carbon atom to which they are bound to form C3-6cycloalkyl;
• RC is selected from the group consisting of hydrogen and C1-3alkyl;
• RD is selected from the group consisting of hydrogen and C1-3alkyl;
• is selected from the group consisting of C5-6cycloalkyl, C5-6cycloalkenyl, phenyl, four to six membered monocyclic heterocyclyl and nine to ten membered bicyclic heterocyclyl;
• wherein the phenyl, four to six membered monocyclic heterocyclyl or nine to ten membered bicyclic heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of halogen, oxo, C1-4alkyl, fluorinated C1-2alkyl, —NRDRE, cyano, imino, cyanoimino, —S—(C1-4alkyl), —SO—(C1-4alkyl), —SO2—(C1-4alkyl), —C(O)OH, —C(O)O—(C1-3alkyl) and —C(O)—NRDRE;
• wherein RD and RE are each independently selected from the group consisting of hydrogen and C1-4alkyl;
• or a tautomer or a pharmaceutically acceptable salt thereof.